Noninferiority test of a sirolimus-ascorbic acid stent vs everolimus stent in heart disease patients
Official title: Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers
Run by Asan Medical Center · NCT07566091 · Data updated 2026-11-12
This study tests whether a sirolimus-ascorbic acid eluting stent works as well as the standard everolimus-eluting stent for people with coronary artery disease undergoing PCI.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 19 Years and up |
| Sex | All |
| Enrollment | 2034 (estimated) |
| Sponsor | Asan Medical Center Academic / other |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | October 6, 2026 |
| Main results expected | June 15, 2027 |
| Study ends | June 15, 2028 |
| Registry record updated | October 7, 2026 |
| Trial ID | NCT07566091 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 19+ with chronic or acute coronary syndromes requiring PCI who can provide informed consent and tolerate dual antiplatelet therapy for 1 year.
✕Probably not a fit
Patients who have eligibility exclusions (e.g., recent cardiogenic shock, known drug hypersensitivities, inability to maintain DAPT, pregnancy) or who do not respond to treatment as intended may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
In patients with chronic or acute coronary syndromes needing PCI, researchers compare the sirolimus-ascorbic acid eluting stent (D+Storm Novonix) to the widely used everolimus-eluting stent (Synergy XD) to see if it is not worse in preventing target lesion failure after one year. Target lesion failure combines cardiovascular death, target vessel heart attack, and need for revascularization at the treated site. The trial uses a noninferiority design to determine if the new stent provides comparable effectiveness and safety. Enrollment is open to adults 19 and older who can consent and meet the PCI criteria, with several safety exclusions in place.
Why it matters
Potential benefit: If successful, patients could have a new stent option that may offer similar protection with potential differences in safety or ease of use.
How similar studies have gone: Previous studies with sirolimus- or everolimus-eluting stents show benefit in PCI, but direct noninferiority data for sirolimus-ascorbic acid stents are needed.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adult men and women aged 19 years or older 2. Patients with chronic coronary syndrome (CCS) or acute coronary syndrome (ACS) who require percutaneous coronary intervention (PCI) (all-comers) 3. Patients who have voluntarily provided written informed consent to participate in the study Exclusion Criteria: 1. Cardiogenic shock within 48 hours prior to the procedure 2. Known hypersensitivity to sirolimus, everolimus, ascorbic acid, or stent components (e.g., cobalt-chromium alloy) 3. Patients unable to maintain dual antiplatelet therapy (DAPT), including aspirin and a P2Y12 inhibitor, for 1 year 4. Women who are pregnant, breastfeeding, or of childbearing potential who meet any of the following: * Have not confirmed a negative pregnancy test prior to enrollment * Do not agree to use, or are unlikely to maintain, an acceptable method of contraception during the study period 5. Clinically significant abnormalities identified during study visits, physical examination, laboratory tests, or electrocardiogram (ECG) that, in the investigator's judgment, may interfere with the safe completion of the study 6. Life expectancy of less than 1 year or presence of serious non-cardiac conditions that may affect compliance with the study protocol 7. Patients who are unwilling or unable to comply with the study protocol
Where it's running
-
Asan Medical Center
Seoul, South Korea Recruiting
Study contacts
- Study coordinator: Jung-hee Ham Project Manager, Registered Nurse
- Email: cvcrc5@amc.seoul.kr
- Phone: 82-2-3010-4728
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
μFR-guided Drug-Coated Balloon Angioplasty vs Angiography-guided Angioplasty in Coronary Artery Disease
This trial tests whether using computational μFR guidance during drug-coated balloon angioplasty is better than standard angiography guidance for people with de novo coronary artery lesions.
-
Gastric Ultrasound Before CABG to See if Heart Function Changes Stomach Contents
This study checks whether people with weaker heart function before elective CABG have different stomach contents seen on ultrasound.
-
Can preoperative photon-counting CT help predict heart recovery after bypass surgery?
This observational study tests whether a preoperative photon-counting CT can help predict heart function 3 months after coronary bypass surgery in adults with coronary artery disease.
-
Real-World Drug-Coated Balloon Angioplasty in Coronary Artery Disease
This registry tests how drug-coated balloons perform in everyday clinical practice for adults with coronary artery disease undergoing PCI.
-
Predicting vasopressor needs after anesthesia in elective on-pump CABG using dynamic arterial elastance
This study tests whether EaDyn measured after induction can help predict which patients will need vasopressors during elective on-pump CABG.
-
Intraoperative Pulse Pressure Variation and Postoperative Lactate Clearance in CABG Patients
This study tests whether the amount a patient’s pulse pressure varies during surgery relates to how quickly lactate levels drop after CABG.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.